-
1
-
-
33846572874
-
Projected number of people with parkinson disease in the most populous nations, 2005 through 2030
-
E. R. Dorsey, R. Constantinescu, J. P. Thompson et al., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030,” Neurology, vol. 68, no. 5, pp. 384–386, 2007.
-
(2007)
Neurology
, vol.68
, Issue.5
, pp. 384-386
-
-
Dorsey, E.R.1
Constantinescu, R.2
Thompson, J.P.3
-
2
-
-
63149090431
-
Parkinson's disease: From monogenic forms to genetic susceptibility factors
-
S. Lesage and A. Brice, “Parkinson's disease: from monogenic forms to genetic susceptibility factors,” Human Molecular Genetics, vol. 18, no. R1, pp. R48–R59, 2009.
-
(2009)
Human Molecular Genetics
, vol.18
, Issue.R1
, pp. R48-R59
-
-
Lesage, S.1
Brice, A.2
-
3
-
-
84992198065
-
The epidemiology of parkinson’s disease: Risk factors and prevention
-
A. Ascherio and M. A. Schwarzschild, “The epidemiology of Parkinson’s disease: risk factors and prevention,” The Lancet Neurology, vol. 15, no. 12, pp. 1257–1272, 2016.
-
(2016)
The Lancet Neurology
, vol.15
, Issue.12
, pp. 1257-1272
-
-
Ascherio, A.1
Schwarzschild, M.A.2
-
4
-
-
71849092190
-
Neuropathological assessment of parkinson’s disease: Refining the diagnostic criteria
-
D. W. Dickson, H. Braak, J. E. Duda et al., “Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria,” The Lancet Neurology, vol. 8, no. 12, pp. 1150–1157, 2009.
-
(2009)
The Lancet Neurology
, vol.8
, Issue.12
, pp. 1150-1157
-
-
Dickson, D.W.1
Braak, H.2
Duda, J.E.3
-
5
-
-
0030882856
-
Α-Synuclein in lewy bodies
-
M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, “α-Synuclein in Lewy bodies,” Nature, vol. 388, no. 6645, pp. 839-840, 1997.
-
(1997)
Nature
, vol.388
, Issue.6645
, pp. 839-840
-
-
Spillantini, M.G.1
Schmidt, M.L.2
Lee, V.M.Y.3
Trojanowski, J.Q.4
Jakes, R.5
Goedert, M.6
-
6
-
-
0037333666
-
Staging of brain pathology related to sporadic parkinson’s disease
-
H. Braak, K. D. Tredici, U. Rüb, R. A. I. de Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson’s disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003.
-
(2003)
Neurobiology of Aging
, vol.24
, Issue.2
, pp. 197-211
-
-
Braak, H.1
Tredici, K.D.2
Rüb, U.3
de Vos, R.A.I.4
Jansen Steur, E.N.H.5
Braak, E.6
-
7
-
-
75949087271
-
Neuroinflammation in parkinson’s disease: Its role in neuronal death and implications for therapeutic intervention
-
M. G. Tansey and M. S. Goldberg, “Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention,” Neurobiology of Disease, vol. 37, no. 3, pp. 510–518, 2010.
-
(2010)
Neurobiology of Disease
, vol.37
, Issue.3
, pp. 510-518
-
-
Tansey, M.G.1
Goldberg, M.S.2
-
8
-
-
0023789193
-
Reactive microglia are positive for HLA-DR in the substantia nigra of parkinson’s and alzheimer’s disease brains
-
P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains,” Neurology, vol. 38, no. 8, pp. 1285–1291, 1988.
-
(1988)
Neurology
, vol.38
, Issue.8
, pp. 1285-1291
-
-
McGeer, P.L.1
Itagaki, S.2
Boyes, B.E.3
McGeer, E.G.4
-
9
-
-
30744472146
-
11C](R)-PK11195 PET in idiopathic parkinson’s disease
-
11C](R)-PK11195 PET in idiopathic Parkinson’s disease,” Neurobiology of Disease, vol. 21, no. 2, pp. 404–412, 2006.
-
(2006)
Neurobiology of Disease
, vol.21
, Issue.2
, pp. 404-412
-
-
Gerhard, A.1
Pavese, N.2
Hotton, G.3
-
10
-
-
28544451467
-
Nonsteroidal antiinflammatory drug use and the risk for parkinson’s disease
-
H. Chen, E. Jacobs, M. A. Schwarzschild et al., “Nonsteroidal antiinflammatory drug use and the risk for Parkinson’s disease,” Annals of Neurology, vol. 58, no. 6, pp. 963–967, 2005.
-
(2005)
Annals of Neurology
, vol.58
, Issue.6
, pp. 963-967
-
-
Chen, H.1
Jacobs, E.2
Schwarzschild, M.A.3
-
11
-
-
58149380755
-
Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of parkinson disease
-
S. Theodore, S. Cao, P. J. McLean, and D. G. Standaert, “Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease,” Journal of Neuropathology & Experimental Neurology, vol. 67, no. 12, pp. 1149–1158, 2008.
-
(2008)
Journal of Neuropathology & Experimental Neurology
, vol.67
, Issue.12
, pp. 1149-1158
-
-
Theodore, S.1
Cao, S.2
McLean, P.J.3
Standaert, D.G.4
-
12
-
-
77649294300
-
Microglia acquire distinct activation profiles depending on the degree of α-synuclein neuropathology in a rAAV based model of parkinson’s disease
-
article
-
V. Sanchez-Guajardo, F. Febbraro, D. Kirik, and M. Romero-Ramos, “Microglia acquire distinct activation profiles depending on the degree of α-synuclein neuropathology in a rAAV based model of Parkinson’s disease,” PLoS One, vol. 5, no. 1, article e8784, 2010.
-
(2010)
PLoS One
, vol.5
, Issue.1
-
-
Sanchez-Guajardo, V.1
Febbraro, F.2
Kirik, D.3
Romero-Ramos, M.4
-
13
-
-
84923491254
-
FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for parkinson’s disease
-
A. Van der Perren, F. Macchi, J. Toelen et al., “FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson’s disease,” Neurobiology of Aging, vol. 36, no. 3, pp. 1559–1568, 2015.
-
(2015)
Neurobiology of Aging
, vol.36
, Issue.3
, pp. 1559-1568
-
-
Van der Perren, A.1
Macchi, F.2
Toelen, J.3
-
14
-
-
85034624068
-
Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of parkinson disease
-
A. S. Harms, A. D. Thome, Z. Yan et al., “Peripheral monocyte entry is required for alpha-synuclein induced inflammation and neurodegeneration in a model of Parkinson disease,” Experimental Neurology, vol. 300, pp. 179–187, 2018.
-
(2018)
Experimental Neurology
, vol.300
, pp. 179-187
-
-
Harms, A.S.1
Thome, A.D.2
Yan, Z.3
-
15
-
-
33845768784
-
Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms
-
M. L. Block, L. Zecca, and J. S. Hong, “Microglia-mediated neurotoxicity: uncovering the molecular mechanisms,” Nature Reviews Neuroscience, vol. 8, no. 1, pp. 57–69, 2007.
-
(2007)
Nature Reviews Neuroscience
, vol.8
, Issue.1
, pp. 57-69
-
-
Block, M.L.1
Zecca, L.2
Hong, J.S.3
-
16
-
-
84983032256
-
The relation between α-synuclein and microglia in parkinson’s disease: Recent developments
-
V. Sanchez-Guajardo, N. Tentillier, and M. Romero-Ramos, “The relation between α-synuclein and microglia in Parkinson’s disease: recent developments,” Neuroscience, vol. 302, pp. 47–58, 2015.
-
(2015)
Neuroscience
, vol.302
, pp. 47-58
-
-
Sanchez-Guajardo, V.1
Tentillier, N.2
Romero-Ramos, M.3
-
17
-
-
70349909667
-
CXCR4 and CXCL12 expression is increased in the nigrostriatal system of parkinson’s disease
-
M. Shimoji, F. Pagan, E. B. Healton, and I. Mocchetti, “CXCR4 and CXCL12 expression is increased in the nigrostriatal system of Parkinson’s disease,” Neurotoxicity Research, vol. 16, no. 3, pp. 318–328, 2009.
-
(2009)
Neurotoxicity Research
, vol.16
, Issue.3
, pp. 318-328
-
-
Shimoji, M.1
Pagan, F.2
Healton, E.B.3
Mocchetti, I.4
-
18
-
-
0030582991
-
Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and parkinson’s disease
-
M. Mogi, M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu, “Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease,” Neuroscience Letters, vol. 211, no. 1, pp. 13–16, 1996.
-
(1996)
Neuroscience Letters
, vol.211
, Issue.1
, pp. 13-16
-
-
Mogi, M.1
Harada, M.2
Narabayashi, H.3
Inagaki, H.4
Minami, M.5
Nagatsu, T.6
-
19
-
-
0028980156
-
Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in parkinson’s disease
-
M. Mogi, M. Harada, T. Kondo, H. Narabayashi, P. Riederer, and T. Nagatsu, “Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson’s disease,” Neuroscience Letters, vol. 193, no. 2, pp. 129–132, 1995.
-
(1995)
Neuroscience Letters
, vol.193
, Issue.2
, pp. 129-132
-
-
Mogi, M.1
Harada, M.2
Kondo, T.3
Narabayashi, H.4
Riederer, P.5
Nagatsu, T.6
-
20
-
-
0028178281
-
Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkin-sonian patients
-
M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu, “Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkin-sonian patients,” Neuroscience Letters, vol. 165, no. 1-2, pp. 208–210, 1994.
-
(1994)
Neuroscience Letters
, vol.165
, Issue.1-2
, pp. 208-210
-
-
Mogi, M.1
Harada, M.2
Riederer, P.3
Narabayashi, H.4
Fujita, K.5
Nagatsu, T.6
-
21
-
-
0033121299
-
FcεRII/CD23 is expressed in parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells
-
S. Hunot, N. Dugas, B. Faucheux et al., “FcεRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-α in glial cells,” The Journal of Neuroscience, vol. 19, no. 9, pp. 3440–3447, 1999.
-
(1999)
The Journal of Neuroscience
, vol.19
, Issue.9
, pp. 3440-3447
-
-
Hunot, S.1
Dugas, N.2
Faucheux, B.3
-
22
-
-
46749085399
-
Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism
-
B. Brodacki, J. Staszewski, B. Toczyłowska et al., “Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism,” Neuroscience Letters, vol. 441, no. 2, pp. 158–162, 2008.
-
(2008)
Neuroscience Letters
, vol.441
, Issue.2
, pp. 158-162
-
-
Brodacki, B.1
Staszewski, J.2
Toczyłowska, B.3
-
23
-
-
37549056264
-
Immune factors or depression? fatigue correlates in parkinson’s disease
-
Z. Katsarou, S. Bostantjopoulou, O. Hatzizisi, E. Giza, A. Soler-Cardona, and G. Kyriazis, “Immune factors or depression? Fatigue correlates in Parkinson’s disease,” Revista de Neurologia, vol. 45, no. 12, pp. 725–728, 2007.
-
(2007)
Revista De Neurologia
, vol.45
, Issue.12
, pp. 725-728
-
-
Katsarou, Z.1
Bostantjopoulou, S.2
Hatzizisi, O.3
Giza, E.4
Soler-Cardona, A.5
Kyriazis, G.6
-
24
-
-
84988584597
-
IL-6 serum levels are elevated in parkinson’s disease patients with fatigue compared to patients without fatigue
-
J. R. Pereira, L. V. . Santos, R. M. S. Santos et al., “IL-6 serum levels are elevated in Parkinson’s disease patients with fatigue compared to patients without fatigue,” Journal of the Neurological Sciences, vol. 370, pp. 153–156, 2016.
-
(2016)
Journal of the Neurological Sciences
, vol.370
, pp. 153-156
-
-
Pereira, J.R.1
Santos, L.V.2
Santos, R.M.S.3
-
25
-
-
79959534690
-
Parkinson’s disease is associated with increased serum levels of macrophage migration inhibitory factor
-
A. Nicoletti, P. Fagone, G. Donzuso et al., “Parkinson’s disease is associated with increased serum levels of macrophage migration inhibitory factor,” Cytokine, vol. 55, no. 2, pp. 165–167, 2011.
-
(2011)
Cytokine
, vol.55
, Issue.2
, pp. 165-167
-
-
Nicoletti, A.1
Fagone, P.2
Donzuso, G.3
-
26
-
-
0029417080
-
Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of alzheimer’s and de novo parkinson’s disease patients
-
D. Blum-Degena, T. Müller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer, “Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients,” Neuroscience Letters, vol. 202, no. 1-2, pp. 17–20, 1995.
-
(1995)
Neuroscience Letters
, vol.202
, Issue.1-2
, pp. 17-20
-
-
Blum-Degena, D.1
Müller, T.2
Kuhn, W.3
Gerlach, M.4
Przuntek, H.5
Riederer, P.6
-
27
-
-
84964555347
-
18F-DPA-714 PET imaging
-
18F-DPA-714 PET imaging,” Brain, vol. 139, no. 4, pp. 1252–1264, 2016.
-
(2016)
Brain
, vol.139
, Issue.4
, pp. 1252-1264
-
-
Hamelin, L.1
Lagarde, J.2
Dorothée, G.3
-
28
-
-
85014843826
-
11C-GSK1482160 for targeting the P2X7 receptor as a biomarker for neuroinflammation
-
11C-GSK1482160 for targeting the P2X7 receptor as a biomarker for neuroinflammation,” The Journal of Nuclear Medicine, vol. 58, no. 3, pp. 458–465, 2017.
-
(2017)
The Journal of Nuclear Medicine
, vol.58
, Issue.3
, pp. 458-465
-
-
Territo, P.R.1
Meyer, J.A.2
Peters, J.S.3
-
29
-
-
84856372105
-
Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: Implications for parkinson’s disease
-
C. Venkateshappa, G. Harish, R. B. Mythri, A. Mahadevan, M. M. Srinivas Bharath, and S. K. Shankar, “Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease,” Neurochemical Research, vol. 37, no. 2, pp. 358–369, 2012.
-
(2012)
Neurochemical Research
, vol.37
, Issue.2
, pp. 358-369
-
-
Venkateshappa, C.1
Harish, G.2
Mythri, R.B.3
Mahadevan, A.4
Srinivas Bharath, M.M.5
Shankar, S.K.6
-
30
-
-
0027434596
-
Glutathione peroxidase, glial cells and parkinson’s disease
-
P. Damier, E. C. Hirsch, P. Zhang, Y. Agid, and F. Javoy-Agid, “Glutathione peroxidase, glial cells and Parkinson’s disease,” Neuroscience, vol. 52, no. 1, pp. 1–6, 1993.
-
(1993)
Neuroscience
, vol.52
, Issue.1
, pp. 1-6
-
-
Damier, P.1
Hirsch, E.C.2
Zhang, P.3
Agid, Y.4
Javoy-Agid, F.5
-
31
-
-
34547727312
-
Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic parkinson’s disease
-
H. Braak, M. Sastre, and K. Del Tredici, “Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson’s disease,” Acta Neuropathologica, vol. 114, no. 3, pp. 231–241, 2007.
-
(2007)
Acta Neuropathologica
, vol.114
, Issue.3
, pp. 231-241
-
-
Braak, H.1
Sastre, M.2
Del Tredici, K.3
-
32
-
-
40949097682
-
A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway
-
M. Z. Gomes, R. Raisman-Vozari, and E. A. Del Bel, “A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway,” Brain Research, vol. 1203, pp. 160–169, 2008.
-
(2008)
Brain Research
, vol.1203
, pp. 160-169
-
-
Gomes, M.Z.1
Raisman-Vozari, R.2
Del Bel, E.A.3
-
33
-
-
33845885123
-
S100B binding to RAGE in microglia stimulates COX-2 expression
-
R. Bianchi, C. Adami, I. Giambanco, and R. Donato, “S100B binding to RAGE in microglia stimulates COX-2 expression,” Journal of Leukocyte Biology, vol. 81, no. 1, pp. 108–118, 2007.
-
(2007)
Journal of Leukocyte Biology
, vol.81
, Issue.1
, pp. 108-118
-
-
Bianchi, R.1
Adami, C.2
Giambanco, I.3
Donato, R.4
-
34
-
-
0023782375
-
Expression of the histocompatibility glycoprotein HLA-DR in neurological disease
-
P. L. McGeer, S. Itagaki, and E. G. McGeer, “Expression of the histocompatibility glycoprotein HLA-DR in neurological disease,” Acta Neuropathologica, vol. 76, no. 6, pp. 550–557, 1988.
-
(1988)
Acta Neuropathologica
, vol.76
, Issue.6
, pp. 550-557
-
-
McGeer, P.L.1
Itagaki, S.2
McGeer, E.G.3
-
35
-
-
58849107919
-
+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of parkinson disease
-
+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease,” The Journal of Clinical Investigation, vol. 119, no. 1, pp. 182–192, 2009.
-
(2009)
The Journal of Clinical Investigation
, vol.119
, Issue.1
, pp. 182-192
-
-
Brochard, V.1
Combadière, B.2
Prigent, A.3
-
36
-
-
0035255035
-
Lymphocyte populations in parkinson’s disease and in rat models of parkinsonism
-
J. Bas, M. Calopa, M. Mestre et al., “Lymphocyte populations in Parkinson’s disease and in rat models of parkinsonism,” Journal of Neuroimmunology, vol. 113, no. 1, pp. 146–152, 2001.
-
(2001)
Journal of Neuroimmunology
, vol.113
, Issue.1
, pp. 146-152
-
-
Bas, J.1
Calopa, M.2
Mestre, M.3
-
37
-
-
34447629515
-
Higher frequency of regulatory t cells in the elderly and increased suppressive activity in neurodegeneration
-
D. Rosenkranz, S. Weyer, E. Tolosa et al., “Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration,” Journal of Neuroimmunology, vol. 188, no. 1-2, pp. 117–127, 2007.
-
(2007)
Journal of Neuroimmunology
, vol.188
, Issue.1-2
, pp. 117-127
-
-
Rosenkranz, D.1
Weyer, S.2
Tolosa, E.3
-
38
-
-
84875860420
-
CD4+ regulatory and effector/memory t cell subsets profile motor dysfunction in parkinson’s disease
-
J. A. H. Saunders, K. A. Estes, L. M. Kosloski et al., “CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson’s disease,” Journal of Neuroimmune Pharmacology, vol. 7, no. 4, pp. 927–938, 2012.
-
(2012)
Journal of Neuroimmune Pharmacology
, vol.7
, Issue.4
, pp. 927-938
-
-
Saunders, J.A.H.1
Estes, K.A.2
Kosloski, L.M.3
-
39
-
-
85021661653
-
T cells from patients with parkinson’s disease recognize α-synuclein peptides
-
D. Sulzer, R. N. Alcalay, F. Garretti et al., “T cells from patients with Parkinson’s disease recognize α-synuclein peptides,” Nature, vol. 546, no. 7660, pp. 656–661, 2017.
-
(2017)
Nature
, vol.546
, Issue.7660
, pp. 656-661
-
-
Sulzer, D.1
Alcalay, R.N.2
Garretti, F.3
-
40
-
-
85027920043
-
Genetics in parkinson disease: Mendelian versus non-mendelian inheritance
-
D. G. Hernandez, X. Reed, and A. B. Singleton, “Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance,” Journal of Neurochemistry, vol. 139, Supplement 1, pp. 59–74, 2016.
-
(2016)
Journal of Neurochemistry
, vol.139
, pp. 59-74
-
-
Hernandez, D.G.1
Reed, X.2
Singleton, A.B.3
-
41
-
-
27644531857
-
A possible role for humoral immunity in the pathogenesis of parkinson’s disease
-
C. F. Orr, D. B. Rowe, Y. Mizuno, H. Mori, and G. M. Halliday, “A possible role for humoral immunity in the pathogenesis of Parkinson’s disease,” Brain, vol. 128, no. 11, pp. 2665–2674, 2005.
-
(2005)
Brain
, vol.128
, Issue.11
, pp. 2665-2674
-
-
Orr, C.F.1
Rowe, D.B.2
Mizuno, Y.3
Mori, H.4
Halliday, G.M.5
-
42
-
-
79953308255
-
Immu-noprotection against toxic biomarkers is retained during parkinson’s disease progression
-
M. A. Gruden, R. D. E. Sewell, K. Yanamandra et al., “Immu-noprotection against toxic biomarkers is retained during Parkinson’s disease progression,” Journal of Neuroimmunology, vol. 233, no. 1-2, pp. 221–227, 2011.
-
(2011)
Journal of Neuroimmunology
, vol.233
, Issue.1-2
, pp. 221-227
-
-
Gruden, M.A.1
Sewell, R.D.E.2
Yanamandra, K.3
-
43
-
-
34247402084
-
Autoantibodies to alpha-synuclein in inherited parkinson’s disease
-
K. K. Papachroni, N. Ninkina, A. Papapanagiotou et al., “Autoantibodies to alpha-synuclein in inherited Parkinson’s disease,” Journal of Neurochemistry, vol. 101, no. 3, pp. 749–756, 2007.
-
(2007)
Journal of Neurochemistry
, vol.101
, Issue.3
, pp. 749-756
-
-
Papachroni, K.K.1
Ninkina, N.2
Papapanagiotou, A.3
-
44
-
-
79955554760
-
Α-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of parkinson’s disease patients
-
article
-
K. Yanamandra, M. A. Gruden, V. Casaite, R. Meskys, L. Forsgren, and L. A. Morozova-Roche, “α-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson’s disease patients,” PLoS One, vol. 6, no. 4, article e18513, 2011.
-
(2011)
PLoS One
, vol.6
, Issue.4
-
-
Yanamandra, K.1
Gruden, M.A.2
Casaite, V.3
Meskys, R.4
Forsgren, L.5
Morozova-Roche, L.A.6
-
45
-
-
84954348724
-
Oligo-meric and phosphorylated alpha-synuclein as potential CSF biomarkers for parkinson’s disease
-
N. K. Majbour, N. N. Vaikath, K. D. van Dijk et al., “Oligo-meric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease,” Molecular Neurodegeneration, vol. 11, no. 1, p. 7, 2016.
-
(2016)
Molecular Neurodegeneration
, vol.11
, Issue.1
, pp. 7
-
-
Majbour, N.K.1
Vaikath, N.N.2
van Dijk, K.D.3
-
46
-
-
85021104422
-
Immunochemical detection of α-synuclein autoanti-bodies in parkinson’s disease: Correlation between plasma and cerebrospinal fluid levels
-
I. Horvath, I. A. Iashchishyn, L. Forsgren, and L. A. Morozova-Roche, “Immunochemical detection of α-synuclein autoanti-bodies in Parkinson’s disease: correlation between plasma and cerebrospinal fluid levels,” ACS Chemical Neuroscience, vol. 8, no. 6, pp. 1170–1176, 2017.
-
(2017)
ACS Chemical Neuroscience
, vol.8
, Issue.6
, pp. 1170-1176
-
-
Horvath, I.1
Iashchishyn, I.A.2
Forsgren, L.3
Morozova-Roche, L.A.4
-
47
-
-
84991094065
-
Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA
-
S. Abd-Elhadi, M. Basora, D. Vilas, E. Tolosa, and R. Sharon, “Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA,” Analytical and Bioana-lytical Chemistry, vol. 408, no. 27, pp. 7669–7677, 2016.
-
(2016)
Analytical and Bioana-Lytical Chemistry
, vol.408
, Issue.27
, pp. 7669-7677
-
-
Abd-Elhadi, S.1
Basora, M.2
Vilas, D.3
Tolosa, E.4
Sharon, R.5
-
48
-
-
33646089430
-
Nonsteroidal anti-inflammatory drugs and the incidence of parkinson disease
-
M. A. Hernán, G. Logroscino, and L. A. G. Rodríguez, “Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease,” Neurology, vol. 66, no. 7, pp. 1097–1099, 2006.
-
(2006)
Neurology
, vol.66
, Issue.7
, pp. 1097-1099
-
-
Hernán, M.A.1
Logroscino, G.2
Rodríguez, L.A.G.3
-
49
-
-
33746894717
-
Nonsteroidal anti-inflammatory drugs and risk of parkinson’s disease
-
T. G. Ton, S. R. Heckbert, W. T. Longstreth Jr et al., “Nonsteroidal anti-inflammatory drugs and risk of Parkinson’s disease,” Movement Disorders, vol. 21, no. 7, pp. 964–969, 2006.
-
(2006)
Movement Disorders
, vol.21
, Issue.7
, pp. 964-969
-
-
Ton, T.G.1
Heckbert, S.R.2
Longstreth, W.T.3
-
50
-
-
84873486299
-
A pathway-based analysis provides additional support for an immune-related genetic susceptibility to parkinson’s disease
-
P. Holmans, V. Moskvina, L. Jones et al., “A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson’s disease,” Human Molecular Genetics, vol. 22, no. 5, pp. 1039–1049, 2013.
-
(2013)
Human Molecular Genetics
, vol.22
, Issue.5
, pp. 1039-1049
-
-
Holmans, P.1
Moskvina, V.2
Jones, L.3
-
51
-
-
79958184746
-
Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes
-
J. Greenbaum, J. Sidney, J. Chung, C. Brander, B. Peters, and A. Sette, “Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes,” Immunogenetics, vol. 63, no. 6, pp. 325–335, 2011.
-
(2011)
Immunogenetics
, vol.63
, Issue.6
, pp. 325-335
-
-
Greenbaum, J.1
Sidney, J.2
Chung, J.3
Brander, C.4
Peters, B.5
Sette, A.6
-
52
-
-
77956646167
-
Common genetic variation in the HLA region is associated with late-onset sporadic parkinson’s disease
-
T. H. Hamza, C. P. Zabetian, A. Tenesa et al., “Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease,” Nature Genetics, vol. 42, no. 9, pp. 781–785, 2010.
-
(2010)
Nature Genetics
, vol.42
, Issue.9
, pp. 781-785
-
-
Hamza, T.H.1
Zabetian, C.P.2
Tenesa, A.3
-
53
-
-
77955759020
-
Association of the human leucocyte antigen region with susceptibility to parkinson’s disease
-
M. Saiki, A. Baker, C. H. Williams-Gray et al., “Association of the human leucocyte antigen region with susceptibility to Parkinson’s disease,” Journal of Neurology, Neurosurgery, & Psychiatry, vol. 81, no. 8, pp. 890-891, 2010.
-
(2010)
Journal of Neurology, Neurosurgery, & Psychiatry
, vol.81
, Issue.8
, pp. 890-891
-
-
Saiki, M.1
Baker, A.2
Williams-Gray, C.H.3
-
54
-
-
84890215976
-
Association of parkinson disease with structural and regulatory variants in the HLA region
-
W. T. Wissemann, E. M. Hill-Burns, C. P. Zabetian et al., “Association of Parkinson disease with structural and regulatory variants in the HLA region,” American Journal of Human Genetics, vol. 93, no. 5, pp. 984–993, 2013.
-
(2013)
American Journal of Human Genetics
, vol.93
, Issue.5
, pp. 984-993
-
-
Wissemann, W.T.1
Hill-Burns, E.M.2
Zabetian, C.P.3
-
55
-
-
84997418152
-
Genome-wide pathway-based association analysis identifies risk pathways associated with parkinson’s disease
-
M. Zhang, H. Mu, Z. Shang et al., “Genome-wide pathway-based association analysis identifies risk pathways associated with Parkinson’s disease,” Neuroscience, vol. 340, pp. 398–410, 2017.
-
(2017)
Neuroscience
, vol.340
, pp. 398-410
-
-
Zhang, M.1
Mu, H.2
Shang, Z.3
-
56
-
-
84945156273
-
Microglial genes regulating neuroinflammation in the progression of alzheimer’s disease
-
C. Villegas-Llerena, A. Phillips, P. Garcia-Reitboeck, J. Hardy, and J. M. Pocock, “Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease,” Current Opinion in Neurobiology, vol. 36, pp. 74–81, 2016.
-
(2016)
Current Opinion in Neurobiology
, vol.36
, pp. 74-81
-
-
Villegas-Llerena, C.1
Phillips, A.2
Garcia-Reitboeck, P.3
Hardy, J.4
Pocock, J.M.5
-
57
-
-
0024322942
-
Microglial response to 6-hydroxydopamine-induced substantia nigra lesions
-
H. Akiyama and P. L. McGeer, “Microglial response to 6-hydroxydopamine-induced substantia nigra lesions,” Brain Research, vol. 489, no. 2, pp. 247–253, 1989.
-
(1989)
Brain Research
, vol.489
, Issue.2
, pp. 247-253
-
-
Akiyama, H.1
McGeer, P.L.2
-
58
-
-
0035800589
-
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
-
Y. He, S. Appel, and W. Le, “Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum,” Brain Research, vol. 909, no. 1-2, pp. 187–193, 2001.
-
(2001)
Brain Research
, vol.909
, Issue.1-2
, pp. 187-193
-
-
He, Y.1
Appel, S.2
Le, W.3
-
59
-
-
0034846276
-
Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine
-
R. W. P. Rodrigues, V. C. Gomide, and G. Chadi, “Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine,” International Journal of Neuroscience, vol. 109, no. 1-2, pp. 91–126, 2009.
-
(2009)
International Journal of Neuroscience
, vol.109
, Issue.1-2
, pp. 91-126
-
-
Rodrigues, R.W.P.1
Gomide, V.C.2
Chadi, G.3
-
60
-
-
50549103590
-
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats
-
M. K. McCoy, K. A. Ruhn, T. N. Martinez, F. E. McAlpine, A. Blesch, and M. G. Tansey, “Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats,” Molecular Therapy, vol. 16, no. 9, pp. 1572–9, 2008.
-
(2008)
Molecular Therapy
, vol.16
, Issue.9
, pp. 1572-1579
-
-
McCoy, M.K.1
Ruhn, K.A.2
Martinez, T.N.3
McAlpine, F.E.4
Blesch, A.5
Tansey, M.G.6
-
61
-
-
0032710609
-
Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of parkinson disease
-
G. T. Liberatore, V. Jackson-Lewis, S. Vukosavic et al., “Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease,” Nature Medicine, vol. 5, no. 12, pp. 1403–1409, 1999.
-
(1999)
Nature Medicine
, vol.5
, Issue.12
, pp. 1403-1409
-
-
Liberatore, G.T.1
Jackson-Lewis, V.2
Vukosavic, S.3
-
62
-
-
0242384667
-
Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration
-
P. L. McGeer, C. Schwab, A. Parent, and D. Doudet, “Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration,” Annals of Neurology, vol. 54, no. 5, pp. 599–604, 2003.
-
(2003)
Annals of Neurology
, vol.54
, Issue.5
, pp. 599-604
-
-
McGeer, P.L.1
Schwab, C.2
Parent, A.3
Doudet, D.4
-
63
-
-
0036522967
-
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson disease
-
D. C. Wu, V. Jackson-Lewis, M. Vila et al., “Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease,” The Journal of Neuroscience, vol. 22, no. 5, pp. 1763–1771, 2002.
-
(2002)
The Journal of Neuroscience
, vol.22
, Issue.5
, pp. 1763-1771
-
-
Wu, D.C.1
Jackson-Lewis, V.2
Vila, M.3
-
64
-
-
38949151035
-
Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons
-
article
-
E. J. Benner, R. Banerjee, A. D. Reynolds et al., “Nitrated α-synuclein immunity accelerates degeneration of nigral dopaminergic neurons,” PLoS One, vol. 3, no. 1, article e1376, 2008.
-
(2008)
PLoS One
, vol.3
, Issue.1
-
-
Benner, E.J.1
Banerjee, R.2
Reynolds, A.D.3
-
65
-
-
36249032567
-
Neuroprotective activities of CD4+CD25+ regulatory t cells in an animal model of parkinson’s disease
-
A. D. Reynolds, R. Banerjee, J. Liu, H. E. Gendelman, and R. Lee Mosley, “Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease,” Journal of Leukocyte Biology, vol. 82, no. 5, pp. 1083–1094, 2007.
-
(2007)
Journal of Leukocyte Biology
, vol.82
, Issue.5
, pp. 1083-1094
-
-
Reynolds, A.D.1
Banerjee, R.2
Liu, J.3
Gendelman, H.E.4
Lee Mosley, R.5
-
66
-
-
84864813232
-
Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein
-
M. B. Watson, F. Richter, S. K. Lee et al., “Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein,” Experimental Neurology, vol. 237, no. 2, pp. 318–334, 2012.
-
(2012)
Experimental Neurology
, vol.237
, Issue.2
, pp. 318-334
-
-
Watson, M.B.1
Richter, F.2
Lee, S.K.3
-
67
-
-
33847363531
-
Wild-type and mutant α-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD
-
R. M. Miller, G. L. Kiser, T. Kaysser-Kranich et al., “Wild-type and mutant α-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD,” Experimental Neurology, vol. 204, no. 1, pp. 421–432, 2007.
-
(2007)
Experimental Neurology
, vol.204
, Issue.1
, pp. 421-432
-
-
Miller, R.M.1
Kiser, G.L.2
Kaysser-Kranich, T.3
-
68
-
-
51449099473
-
Synuclein activates microglia in a model of parkinson’s disease
-
X. Su, K. A. Maguire-Zeiss, R. Giuliano, L. Prifti, K. Venkatesh, and H. J. Federoff, “Synuclein activates microglia in a model of Parkinson’s disease,” Neurobiology of Aging, vol. 29, no. 11, pp. 1690–1701, 2008.
-
(2008)
Neurobiology of Aging
, vol.29
, Issue.11
, pp. 1690-1701
-
-
Su, X.1
Maguire-Zeiss, K.A.2
Giuliano, R.3
Prifti, L.4
Venkatesh, K.5
Federoff, H.J.6
-
69
-
-
33646097224
-
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1-120): Implications for lewy body disorders
-
G. K. Tofaris, P. Garcia Reitböck, T. Humby et al., “Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein(1-120): implications for Lewy body disorders,” The Journal of Neuroscience, vol. 26, no. 15, pp. 3942–3950, 2006.
-
(2006)
The Journal of Neuroscience
, vol.26
, Issue.15
, pp. 3942-3950
-
-
Tofaris, G.K.1
Garcia Reitböck, P.2
Humby, T.3
-
70
-
-
84892150877
-
Structural and functional characterization of two alpha-synuclein strains
-
article
-
L. Bousset, L. Pieri, G. Ruiz-Arlandis et al., “Structural and functional characterization of two alpha-synuclein strains,” Nature Communications, vol. 4, article 2575, 2013.
-
(2013)
Nature Communications
, vol.4
-
-
Bousset, L.1
Pieri, L.2
Ruiz-Arlandis, G.3
-
71
-
-
84934983329
-
Α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
-
W. Peelaerts, L. Bousset, A. van der Perren et al., “α-Synuclein strains cause distinct synucleinopathies after local and systemic administration,” Nature, vol. 522, no. 7556, pp. 340–344, 2015.
-
(2015)
Nature
, vol.522
, Issue.7556
, pp. 340-344
-
-
Peelaerts, W.1
Bousset, L.2
van der Perren, A.3
-
72
-
-
82155168545
-
The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation
-
Y. Couch, L. Alvarez-Erviti, N. R. Sibson, M. J. A. Wood, and D. C. Anthony, “The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation,” Journal of Neuroinflammation, vol. 8, no. 1, p. 166, 2011.
-
(2011)
Journal of Neuroinflammation
, vol.8
, Issue.1
, pp. 166
-
-
Couch, Y.1
Alvarez-Erviti, L.2
Sibson, N.R.3
Wood, M.J.A.4
Anthony, D.C.5
-
73
-
-
76349097346
-
Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by α-synuclein protofibrils
-
H. Wilms, P. Rosenstiel, M. Romero-Ramos et al., “Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by α-synuclein protofibrils,” International Journal of Immunopathology and Pharmacology, vol. 22, no. 4, pp. 897–909, 2009.
-
(2009)
International Journal of Immunopathology and Pharmacology
, vol.22
, Issue.4
, pp. 897-909
-
-
Wilms, H.1
Rosenstiel, P.2
Romero-Ramos, M.3
-
74
-
-
85010424593
-
The effect of α-synu-clein on gliosis and IL-1α, TNFα, IFNγ, TGFβ expression in murine brain
-
A. Sznejder-Pachołek, I. Joniec-Maciejak, A. Wawer, A. Ciesielska, and D. Mirowska-Guzel, “The effect of α-synu-clein on gliosis and IL-1α, TNFα, IFNγ, TGFβ expression in murine brain,” Pharmacological Reports, vol. 69, no. 2, pp. 242–251, 2017.
-
(2017)
Pharmacological Reports
, vol.69
, Issue.2
, pp. 242-251
-
-
Sznejder-Pachołek, A.1
Joniec-Maciejak, I.2
Wawer, A.3
Ciesielska, A.4
Mirowska-Guzel, D.5
-
75
-
-
85043597871
-
Α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration
-
A. S. Harms, V. Delic, A. D. Thome et al., “α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration,” Acta Neuropathologica Communications, vol. 5, no. 1, p. 85, 2017.
-
(2017)
Acta Neuropathologica Communications
, vol.5
, Issue.1
, pp. 85
-
-
Harms, A.S.1
Delic, V.2
Thome, A.D.3
-
76
-
-
44749090147
-
Clearance and deposition of extracellular α-synuclein aggregates in microglia
-
H. J. Lee, J. E. Suk, E. J. Bae, and S. J. Lee, “Clearance and deposition of extracellular α-synuclein aggregates in microglia,” Biochemical and Biophysical Research Communications, vol. 372, no. 3, pp. 423–428, 2008.
-
(2008)
Biochemical and Biophysical Research Communications
, vol.372
, Issue.3
, pp. 423-428
-
-
Lee, H.J.1
Suk, J.E.2
Bae, E.J.3
Lee, S.J.4
-
77
-
-
70349574622
-
Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease
-
S. Higashi, D. J. Moore, R. Yamamoto et al., “Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease,” Journal of Neuropathology & Experimental Neurology, vol. 68, no. 9, pp. 994–1005, 2009.
-
(2009)
Journal of Neuropathology & Experimental Neurology
, vol.68
, Issue.9
, pp. 994-1005
-
-
Higashi, S.1
Moore, D.J.2
Yamamoto, R.3
-
78
-
-
80855131625
-
Meta-analysis of published studies identified eight additional common susceptibility loci for crohn’s disease and ulcerative colitis
-
J. Umeno, K. Asano, T. Matsushita et al., “Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn’s disease and ulcerative colitis,” Inflammatory Bowel Diseases, vol. 17, no. 12, pp. 2407–2415, 2011.
-
(2011)
Inflammatory Bowel Diseases
, vol.17
, Issue.12
, pp. 2407-2415
-
-
Umeno, J.1
Asano, K.2
Matsushita, T.3
-
79
-
-
78149473340
-
LRRK2 is involved in the IFN-γ response and host response to pathogens
-
A. Gardet, Y. Benita, C. Li et al., “LRRK2 is involved in the IFN-γ response and host response to pathogens,” The Journal of Immunology, vol. 185, no. 9, pp. 5577–5585, 2010.
-
(2010)
The Journal of Immunology
, vol.185
, Issue.9
, pp. 5577-5585
-
-
Gardet, A.1
Benita, Y.2
Li, C.3
-
80
-
-
84902163498
-
Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy
-
J. Schapansky, J. D. Nardozzi, F. Felizia, and M. J. LaVoie, “Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy,” Human Molecular Genetics, vol. 23, no. 16, pp. 4201–4214, 2014.
-
(2014)
Human Molecular Genetics
, vol.23
, Issue.16
, pp. 4201-4214
-
-
Schapansky, J.1
Nardozzi, J.D.2
Felizia, F.3
LaVoie, M.J.4
-
81
-
-
84856632181
-
LRRK2 inhibition attenuates microglial inflammatory responses
-
M. S. Moehle, P. J. Webber, T. Tse et al., “LRRK2 inhibition attenuates microglial inflammatory responses,” The Journal of Neuroscience, vol. 32, no. 5, pp. 1602–1611, 2012.
-
(2012)
The Journal of Neuroscience
, vol.32
, Issue.5
, pp. 1602-1611
-
-
Moehle, M.S.1
Webber, P.J.2
Tse, T.3
-
82
-
-
84949650757
-
Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells
-
I. Russo, G. Berti, N. Plotegher et al., “Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells,” Journal of Neuroinflammation, vol. 12, no. 1, p. 230, 2015.
-
(2015)
Journal of Neuroinflammation
, vol.12
, Issue.1
, pp. 230
-
-
Russo, I.1
Berti, G.2
Plotegher, N.3
-
83
-
-
72149087091
-
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by parkinson’s-disease-related mutant α-synuclein
-
X. Lin, L. Parisiadou, X. L. Gu et al., “Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant α-synuclein,” Neuron, vol. 64, no. 6, pp. 807–827, 2009.
-
(2009)
Neuron
, vol.64
, Issue.6
, pp. 807-827
-
-
Lin, X.1
Parisiadou, L.2
Gu, X.L.3
-
84
-
-
84866145895
-
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain
-
article
-
M. C. Herzig, M. Bidinosti, T. Schweizer et al., “High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain,” PLoS One, vol. 7, no. 5, article e36581, 2012.
-
(2012)
PLoS One
, vol.7
, Issue.5
-
-
Herzig, M.C.1
Bidinosti, M.2
Schweizer, T.3
-
85
-
-
84861162180
-
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2
-
J. P. L. Daher, O. Pletnikova, S. Biskup et al., “Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2,” Human Molecular Genetics, vol. 21, no. 11, pp. 2420–2431, 2012.
-
(2012)
Human Molecular Genetics
, vol.21
, Issue.11
, pp. 2420-2431
-
-
Daher, J.P.L.1
Pletnikova, O.2
Biskup, S.3
-
86
-
-
84903435402
-
Abrogation of α-synuclein-medi-ated dopaminergic neurodegeneration in LRRK2-deficient rats
-
J. P. L. Daher, L. A. Volpicelli-Daley, J. P. Blackburn, M. S. Moehle, and A. B. West, “Abrogation of α-synuclein-medi-ated dopaminergic neurodegeneration in LRRK2-deficient rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 25, pp. 9289–9294, 2014.
-
(2014)
Proceedings of the National Academy of Sciences of the United States of America
, vol.111
, Issue.25
, pp. 9289-9294
-
-
Daher, J.P.L.1
Volpicelli-Daley, L.A.2
Blackburn, J.P.3
Moehle, M.S.4
West, A.B.5
-
87
-
-
84939145610
-
Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration
-
J. P. L. Daher, H. A. Abdelmotilib, X. Hu et al., “Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration,” The Journal of Biological Chemistry, vol. 290, no. 32, pp. 19433–19444, 2015.
-
(2015)
The Journal of Biological Chemistry
, vol.290
, Issue.32
, pp. 19433-19444
-
-
Daher, J.P.L.1
Abdelmotilib, H.A.2
Hu, X.3
-
88
-
-
5444255434
-
Stages in the development of parkinson’s disease-related pathology
-
H. Braak, E. Ghebremedhin, U. Rüb, H. Bratzke, and K. del Tredici, “Stages in the development of Parkinson’s disease-related pathology,” Cell and Tissue Research, vol. 318, no. 1, pp. 121–134, 2004.
-
(2004)
Cell and Tissue Research
, vol.318
, Issue.1
, pp. 121-134
-
-
Braak, H.1
Ghebremedhin, E.2
Rüb, U.3
Bratzke, H.4
del Tredici, K.5
-
89
-
-
79551519276
-
Α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells
-
C. Hansen, E. Angot, A. L. Bergström et al., “α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells,” The Journal of Clinical Investigation, vol. 121, no. 2, pp. 715–725, 2011.
-
(2011)
The Journal of Clinical Investigation
, vol.121
, Issue.2
, pp. 715-725
-
-
Hansen, C.1
Angot, E.2
Bergström, A.L.3
-
90
-
-
75749135592
-
A timeline for parkinson’s disease
-
C. H. Hawkes, K. Del Tredici, and H. Braak, “A timeline for Parkinson’s disease,” Parkinsonism & Related Disorders, vol. 16, no. 2, pp. 79–84, 2010.
-
(2010)
Parkinsonism & Related Disorders
, vol.16
, Issue.2
, pp. 79-84
-
-
Hawkes, C.H.1
Del Tredici, K.2
Braak, H.3
-
91
-
-
77958558412
-
Colonic biopsies to assess the neuropathology of parkinson’s disease and its relationship with symptoms
-
article
-
T. Lebouvier, M. Neunlist, S. Bruley des Varannes et al., “Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms,” PLoS One, vol. 5, no. 9, article e12728, 2010.
-
(2010)
PLoS One
, vol.5
, Issue.9
-
-
Lebouvier, T.1
Neunlist, M.2
Bruley des Varannes, S.3
-
92
-
-
0026609580
-
Gastrointestinal dysfunction in parkinson’s disease: Frequency and pathophysiology
-
L. L. Edwards, E. M. M. Quigley, and R. F. Pfeiffer, “Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology,” Neurology, vol. 42, no. 4, pp. 726–732, 1992.
-
(1992)
Neurology
, vol.42
, Issue.4
, pp. 726-732
-
-
Edwards, L.L.1
Quigley, E.M.M.2
Pfeiffer, R.F.3
-
93
-
-
32544442518
-
Gastric α-synuclein immunoreactive inclusions in meissner’s and auerbach’s plexuses in cases staged for parkinson’s disease-related brain pathology
-
H. Braak, R. A. I. de Vos, J. Bohl, and K. del Tredici, “Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology,” Neuroscience Letters, vol. 396, no. 1, pp. 67–72, 2006.
-
(2006)
Neuroscience Letters
, vol.396
, Issue.1
, pp. 67-72
-
-
Braak, H.1
de Vos, R.A.I.2
Bohl, J.3
del Tredici, K.4
-
94
-
-
77953021942
-
Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with lewy body disorders
-
T. G. Beach, C. H. Adler, L. I. Sue et al., “Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders,” Acta Neuropathologica, vol. 119, no. 6, pp. 689–702, 2010.
-
(2010)
Acta Neuropathologica
, vol.119
, Issue.6
, pp. 689-702
-
-
Beach, T.G.1
Adler, C.H.2
Sue, L.I.3
-
95
-
-
82455206282
-
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early parkinson’s disease
-
article
-
C. B. Forsyth, K. M. Shannon, J. H. Kordower et al., “Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease,” PLoS One, vol. 6, no. 12, article e28032, 2011.
-
(2011)
PLoS One
, vol.6
, Issue.12
-
-
Forsyth, C.B.1
Shannon, K.M.2
Kordower, J.H.3
-
96
-
-
84924577956
-
Gut microbiota are related to parkinson’s disease and clinical phenotype
-
F. Scheperjans, V. Aho, P. A. B. Pereira et al., “Gut microbiota are related to Parkinson’s disease and clinical phenotype,” Movement Disorders, vol. 30, no. 3, pp. 350–358, 2015.
-
(2015)
Movement Disorders
, vol.30
, Issue.3
, pp. 350-358
-
-
Scheperjans, F.1
Aho, V.2
Pereira, P.A.B.3
-
97
-
-
0141514778
-
Immune system and peripheral nerves in propagation of prions to CNS
-
A. Aguzzi, F. L. Heppner, M. Heikenwalder et al., “Immune system and peripheral nerves in propagation of prions to CNS,” British Medical Bulletin, vol. 66, no. 1, pp. 141–159, 2003.
-
(2003)
British Medical Bulletin
, vol.66
, Issue.1
, pp. 141-159
-
-
Aguzzi, A.1
Heppner, F.L.2
Heikenwalder, M.3
-
98
-
-
78650880194
-
Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of parkinson’s disease
-
A. S. Harms, C. J. Barnum, K. A. Ruhn et al., “Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson’s disease,” Molecular Therapy, vol. 19, no. 1, pp. 46–52, 2011.
-
(2011)
Molecular Therapy
, vol.19
, Issue.1
, pp. 46-52
-
-
Harms, A.S.1
Barnum, C.J.2
Ruhn, K.A.3
-
99
-
-
3042592589
-
Therapeutic immunization protects dopaminergic neurons in a mouse model of parkinson’s disease
-
E. J. Benner, R. L. Mosley, C. J. Destache et al., “Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 25, pp. 9435–9440, 2004.
-
(2004)
Proceedings of the National Academy of Sciences of the United States of America
, vol.101
, Issue.25
, pp. 9435-9440
-
-
Benner, E.J.1
Mosley, R.L.2
Destache, C.J.3
-
100
-
-
11144256197
-
Halt of celebrex study threatens drug’s future, other trials
-
J. Couzin, “Halt of Celebrex study threatens drug’s future, other trials,” Science, vol. 306, no. 5705, p. 2170, 2004.
-
(2004)
Science
, vol.306
, Issue.5705
, pp. 2170
-
-
Couzin, J.1
-
101
-
-
0034008991
-
Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats
-
X. Lu, G. Bing, and T. Hagg, “Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats,” Neuroscience, vol. 97, no. 2, pp. 285–291, 2000.
-
(2000)
Neuroscience
, vol.97
, Issue.2
, pp. 285-291
-
-
Lu, X.1
Bing, G.2
Hagg, T.3
-
102
-
-
0347087323
-
Protection by pioglitazone in the MPTP model of parkinson’s disease correlates with IκBα induction and block of NFκB and iNOS activation
-
T. Dehmer, M. T. Heneka, M. Sastre, J. Dichgans, and J. B. Schulz, “Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with IκBα induction and block of NFκB and iNOS activation,” Journal of Neurochemistry, vol. 88, no. 2, pp. 494–501, 2004.
-
(2004)
Journal of Neurochemistry
, vol.88
, Issue.2
, pp. 494-501
-
-
Dehmer, T.1
Heneka, M.T.2
Sastre, M.3
Dichgans, J.4
Schulz, J.B.5
-
103
-
-
20444413356
-
Effects of α-synuclein immunization in a mouse model of parkinson’s disease
-
E. Masliah, E. Rockenstein, A. Adame et al., “Effects of α-synuclein immunization in a mouse model of Parkinson’s disease,” Neuron, vol. 46, no. 6, pp. 857–868, 2005.
-
(2005)
Neuron
, vol.46
, Issue.6
, pp. 857-868
-
-
Masliah, E.1
Rockenstein, E.2
Adame, A.3
-
104
-
-
84879934105
-
Α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory t cell recruitment in a rat model
-
V. Sanchez-Guajardo, A. Annibali, P. H. Jensen, and M. Romero-Ramos, “α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model,” Journal of Neuropathology & Experimental Neurology, vol. 72, no. 7, pp. 624–645, 2013.
-
(2013)
Journal of Neuropathology & Experimental Neurology
, vol.72
, Issue.7
, pp. 624-645
-
-
Sanchez-Guajardo, V.1
Annibali, A.2
Jensen, P.H.3
Romero-Ramos, M.4
-
105
-
-
84901682081
-
Next-generation active immunization approach for synucleinopathies: Implications for parkinson’s disease clinical trials
-
M. Mandler, E. Valera, E. Rockenstein et al., “Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials,” Acta Neuropathologica, vol. 127, no. 6, pp. 861–879, 2014.
-
(2014)
Acta Neuropathologica
, vol.127
, Issue.6
, pp. 861-879
-
-
Mandler, M.1
Valera, E.2
Rockenstein, E.3
-
106
-
-
79955757052
-
Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease
-
article
-
E. Masliah, E. Rockenstein, M. Mante et al., “Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease,” PLoS One, vol. 6, no. 4, article e19338, 2011.
-
(2011)
PLoS One
, vol.6
, Issue.4
-
-
Masliah, E.1
Rockenstein, E.2
Mante, M.3
-
107
-
-
84866679781
-
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission
-
E. J. Bae, H. J. Lee, E. Rockenstein et al., “Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission,” The Journal of Neuroscience, vol. 32, no. 39, pp. 13454–13469, 2012.
-
(2012)
The Journal of Neuroscience
, vol.32
, Issue.39
, pp. 13454-13469
-
-
Bae, E.J.1
Lee, H.J.2
Rockenstein, E.3
-
108
-
-
84879419913
-
Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation
-
T. Fagerqvist, V. Lindström, E. Nordström et al., “Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation,” Journal of Neurochemistry, vol. 126, no. 1, pp. 131–144, 2013.
-
(2013)
Journal of Neurochemistry
, vol.126
, Issue.1
, pp. 131-144
-
-
Fagerqvist, T.1
Lindström, V.2
Nordström, E.3
|